Brief: Acurx Presents Positive Ibezapolstat Microbiome Data From Its Phase 2A Trial At IDWeek
04/10/2021 14:05
Oct 4 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX PRESENTS POSITIVE IBEZAPOLSTAT MICROBIOME DATA FROM
ITS
PHASE 2A TRIAL AT IDWEEK
* ACURX PHARMACEUTICALS INC - PH2A TRIAL DEMONSTRATED 100%
CLINICAL CURE AND SUSTAINED CLINICAL CURE
Source text for Eikon: ID:nPnbDQQ22a
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsBrief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program